---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-22-009659"
form_type: "8-K"
ticker: "NKTX"
cik: "0001787400"
company_name: "Nkarta, Inc."
filed_at: "2022-05-12T23:59:59+00:00"
generated_at: "2026-06-25T19:02:16.344208+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Nkarta reports Q1 net loss $26.0M; shares positive AML/NHL clinical data

## Summary
- Net loss $26.0M ($0.79/share); cash, equivalents & short-term investments $219.1M at 3/31/22, plus $215.5M net from April offering, pro forma >$400M.
- NKX101 Phase 1: 3 of 5 heavily pre-treated AML patients at higher dose achieved complete response; 2 of 3 CRs MRD-negative.
- NKX019 Phase 1: 5 of 6 NHL patients responded, 3 CR (including DLBCL and MCL); no CRS, GvHD, or ICANS observed in either study.
- Anticipates additional NKX101 and NKX019 dose-escalation data in H2 2022.
- Angela Thedinga appointed to Board of Directors in March 2022.

## SEC filing metadata
- accession: 0000950170-22-009659
- form_type: 8-K
- ticker: NKTX
- cik: 0001787400
- company_name: Nkarta, Inc.
- filed_at: 2022-05-12T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1787400/000095017022009659/0000950170-22-009659-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1787400/000095017022009659/nktx-20220512.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-22-009659
- JSON: https://secwatch.observer/filing/0000950170-22-009659.json
- Plain text: https://secwatch.observer/filing/0000950170-22-009659.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.